GT Biopharma Files Q1 2025 10-Q
Ticker: GTBP · Form: 10-Q · Filed: May 15, 2025 · CIK: 109657
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
GT Biopharma filed its Q1 2025 10-Q. Business as usual.
AI Summary
GT Biopharma, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 505 Montgomery Street, San Francisco, CA.
Why It Matters
This filing provides investors with an update on GT Biopharma's financial performance and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a standard quarterly filing with no immediately apparent significant negative or positive events.
Key Players & Entities
- GT Biopharma, Inc. (company) — Filer
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
- 20250331 (date) — Reporting Period End Date
- 20250515 (date) — Filing Date
- 505 MONTGOMERY STREET (address) — Business Address
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the first quarter of 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20250515.
What is the primary business of GT Biopharma, Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What are GT Biopharma's former company names?
GT Biopharma was formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.
Where are GT Biopharma's principal business offices located?
The company's business address is 505 MONTGOMERY STREET, 10TH FLOOR, SAN FRANCISCO, CA 94111.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding GT Biopharma, Inc. (GTBP).